Valeant Pharmaceuticals International

Type: Company
Name: Valeant Pharmaceuticals International
First reported 40 mins ago - Updated 40 mins ago - 1 reports

Earnings Scheduled For October 20, 2014

Halliburton Company (NYSE: HAL) is estimated to report its Q3 earnings at $1.10 per share on revenue of $8.53 billion. Apple (NASDAQ: ...Related Stocks:Apple Inc. BANCORPSOUTH, Inc. BANK OF MARIN BROWN & BROWN, Inc. CELANESE CORPORATION CHIPOTLE MEXICAN ... [Published MoneyShow.com - 40 mins ago]
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Earnings continue to lead agenda

This week's agenda continues to focus on earnings, though there are some economic reports and global events.Halliburton, VF Corporation, Valeant Pharmaceuticals, and Peabody Energy report this morning. Apple, IBM, and Texas Instruments follow in the afternoon. ... [Published Option Monster - 2 hours ago]
First reported Oct 16 2014 - Updated Oct 17 2014 - 16 reports

Ackman Says He Has Proof Allergan Lied About Valeant

Allergan Inc. has been lying about would-be buyer Valeant Pharmaceuticals International, Pershing Square Capital Management founder William Ackman said yesterday.Ackman, Allergan’s largest shareholder, said that his lawyers have seen documents showing ... [Published FINalternatives - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

TSX poised to open higher ahead of inflation data

(Reuters) - Stock futures pointed to a higher opening for Canada's main stock index on Friday, with December futures on the S&P TSX index up 1.04 percent at 0720 ET.Inflation data is due at 0830 ET .The Toronto Stock Exchange 300 Composite Index <.GSPTSE> ... [Published 4 Traders - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 17 2014 - 1 reports

Matchmaking for Shire and AbbVie already? Try Allergan (of course) and Pfizer

Now that AbbVie ($ABBV) has said it wants to dump Shire ($SHPG), we could soon have two companies back on the market--and both could prove popular as the dust settles. In fact, as Bloomberg reports, AbbVie could make a decent second choice to AstraZeneca ... [Published FiercePharma - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Update: TSX Rallies 180 Points as Gains in Energy Stocks Offset Global Growth Concerns

The energy sector climbed nearly 4%, snapping an 11-day losing streak, and railway stocks boosted the industrial sector, up 2.5%. Financials gained 0.7% as bank shares rose.Heavily traded Canadian Natural Resources (CNQ.TO) added 4% while Suncor Energy ... [Published Nasdaq - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Will Activis Win Competition For Allergan's Affection?

Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possi ... [Published Benzinga.com - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014

LAVAL, Quebec, Oct. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, October 20, ... [Published PR Newswire: Health - Oct 15 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Gilead, Allergan, Novo and Valeant chiefs make the list of world's top 10

Gilead CEO John MartinPharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned. Four of them--Gilead Sciences' ( $GILD ) John Martin, Allergan's ( $AGN ) David Pyott, Novo Nordisk's ( $NVO ) Lars Rebien ... [Published FiercePharma - Oct 15 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Letter: Time will tell for Valeant, B+L

Bausch + Lomb manufacturing facility at 1400 N. Goodman St. in Rochester.Bausch + Lomb manufacturing facility at 1400 N. Goodman St. in Rochester. lessWhile I am pleased to hear that Bausch + Lomb is doing well under Valeant leadership, I think Sunday’s ... [Published Rochester Democrat and Chronicle - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Potential Valeant Pharmac. (VRX) Trade Targets 8.20% Return

Valeant Pharmac. (VRX) was identified by MarketIntelligenceCenter.com’s patented algorithms today after trading between $113.49 and $120.54 on Monday before closing at $113.56. A diagonal spread using a long position in the Jan. '16 $55.00 call and a ... [Published MarketIntelligenceCenter.com - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 2 reports

Bill Ackman's New Fund Falls 6% In Public Debut In Amsterdam

NEW YORK –   Hedge fund manager Bill Ackman's Pershing Square Holdings fell nearly 7% in its debut as a public company on Monday. The new company was listed in Amsterdam at an offering price of $25 a share, valuing it at $6.2 billion. Ackman formed the ... [Published FOXBusiness.com - Oct 13 2014]

Quotes

"The breadth and scope of the changes, including the unexpected nature of the exercise of administrative authority to impact longstanding tax principles, and to target specifically a subset of companies that would be treated differently than either other inverted companies or foreign domiciled entities, introduced an unacceptable level of uncertainty to the transaction. Additionally, the changes eliminated certain of the financial benefits of the transaction, most notably the ability to access current and future global cash flows in a tax efficient manner as originally contemplated in the transaction. This fundamentally changed the implied value of Shire to AbbVie in a significant manner."
"They have consciously put out materially false and misleading information about Valeant's business and accounting. They called it a house of cards and said it will collapse in the third quarter and Bausch & Lomb sales are going to decline" he said, adding the information will be given to Canadian and U S securities regulators
"We've actually found evidence that will come outout in the next few days of attempts at manipulating Valeant's stock price down" Ackman said, noting that he has not seen that evidence because it has been marked as "highly confidential."
...Ackman remarked that "this was a conscious takeover defence strategy to malign Valeant and their accounting and the stock price, and they didn't believe what they were saying when they made those statements."

More Content

All (1754) | News (1057) | Reports (0) | Blogs (647) | Audio/Video (15) | Fact Sheets (2) | Press Releases (30)
sort by: Date | Relevance
Earnings Scheduled For October 20, 2014 [Published MoneyShow.com - 40 mins ago]
Earnings Scheduled For October 20, 2014 [Published Benzinga.com - 43 mins ago]
Earnings continue to lead agenda [Published Option Monster - 2 hours ago]
Merger Arbitrage Carnage May Continue Due To Ab... [Published Seeking Alpha - Oct 17 2014]
A sharp learning curve for Cold-FX inventor [Published CanadExport - Oct 17 2014]
Five things for pharma marketers to know: Frida... [Published Medical Marketing And Media - Oct 17 2014]
World’s Top 10 Best-Performing CEOs Revealed [Published Dubai Chronicle - Oct 17 2014]
Ackman: Canada Better Than U.S. For Activists [Published FINalternatives - Oct 17 2014]
Ackman Says He Has Proof Allergan Lied About Va... [Published FINalternatives - Oct 17 2014]
Faber Report: Allergan takeover battle [Published CNBC - Oct 17 2014]
Globe says Valeant ally Ackman makes Allergan t... [Published Stockwatch - Oct 17 2014]
Lawyers Have Documents That Prove Allergan Inc.... [Published BioSpace - Oct 17 2014]
Valeant Pharmac. (VRX) Showing Bearish Technica... [Published MarketIntelligenceCenter.com - Oct 17 2014]
TSX poised to open higher ahead of inflation data [Published Yahoo! Malaysia - Oct 17 2014]
CANADA STOCKS-TSX poised to open higher ahead o... [Published Reuters - Oct 17 2014]
TSX poised to open higher ahead of inflation data [Published 4 Traders - Oct 17 2014]
Diabetic Retinopathy Market: Global Industry An... [Published MyNewsDesk - Oct 17 2014]
Canadian stock rallies as positive data eases f... [Published Individual.com - Oct 17 2014]
AbbVie-free Shire could open new opportunities [Published Medical Marketing And Media - Oct 16 2014]
Hottest Healthcare Stocks Now – HCA NKTR THC NBIX [Published InvestorPlace.com - Oct 16 2014]
Stock markets finish mixed; unemployment applic... [Published Cleveland.com - Oct 16 2014]
Wally Weitz Q3 2014 Shareholder Letter [Published Guru Focus - Oct 16 2014]
Stock Update (NYSE:AGN): Ackman: Lawyers have d... [Published Jutia Group - Oct 16 2014]
Cairns given perjury trial date [Published Yahoo! Maktoob News - Oct 16 2014]
Bill Ackman: Canada ‘a better regime in almost ... [Published Financial Post - Top Stories - Oct 16 2014]
Update: TSX Rallies 180 Points as Gains in Ener... [Published Nasdaq - Oct 16 2014]
Ackman Has Evidence Of Misleading Allergan Stat... [Published Value Walk - Oct 16 2014]
Pershing Square's William Ackman says found evi... [Published FirstWord Pharma - Oct 16 2014]
Stock Update (NYSE:AGN): Ackman: Lawyers have d... [Published Wall Street Select - Oct 16 2014]
UPDATE 1-Ackman: Lawyers have documents purport... [Published Reuters UK - Oct 16 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Valeant Pharmac. (VRX) Showing Bearish Technica... [Published MarketIntelligenceCenter.com - Oct 17 2014]
Thursday’s trading in Valeant Pharmac. (VRX) gives options traders an opportunity for a 7.05% return. By selling the Jan. '15 $115.00 call and buying the Jan. '16 call at the $55.00 level for a net debit of $56.05, traders will book a profit as long as ...
Bill Ackman: Canada ‘a better regime in almost ... [Published Financial Post - Top Stories - Oct 16 2014]
Canada’s rules on poison-pills and the relative ease with which investors can call for shareholder meetings make the country a friendlier place for shareholder activists than the U.S., said Bill Ackman, the billionaire hedge-fund manager. “It’s a better ...
Ackman: Lawyers Have Documents Purported To Sho... [Published Clusterstock - Oct 16 2014]
TORONTO (Reuters) - Hedge fund manager Bill Ackman said on Thursday his lawyers have seen documents that he said show Allergan's board knowingly misled investors as part of a defensive strategy to stave off prospective buyer Valeant Pharmaceuticals ...
Valeant Pharmac. (VRX) Trading Near $117.12 Res... [Published MarketIntelligenceCenter.com - Oct 16 2014]
A covered call identified by MarketIntelligececenter.com's patented algorithms on Valeant Pharmac. (VRX) could yield about 6.14% (24.08% annualized, for comparison purposes only) in 93 days. Pair a long position in the stock with the Jan. '15 $110.00 ...
Valeant Pharmaceuticals To Announce 2014 Third ... [Published PR Newswire: Health - Oct 15 2014]
LAVAL, Quebec, Oct. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, October 20, ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Breakingviews: The trials of the $57 bn drug deal [Published Reuters Video: Top News - Oct 09 2014]
Breakingviews: The trials of the $57 bn drug deal [Published Reuters Video: Business - Oct 09 2014]
Financial Stocks Help Lift The Major Indexes [Published Wall Street Journal What's News - Jun 17 2014]
Breakingviews: Snapchat for bankers? [Published Reuters Video: Top News - Jun 16 2014]
Breakingviews: Snapchat for bankers? [Published Reuters Video: Business - Jun 16 2014]
1 2 3

Press Releases

sort by: Date | Relevance
Critical Alerts For Cliffs Natural Resources, V... [Published Financial Services - Oct 14 2014]
Positive Study Results, Dividend, Regulatory Wa... [Published Financial Services - Oct 07 2014]
IGI Laboratories, Inc. Acquires Two Products Fr... [Published Financial Services - Oct 01 2014]
Scanning Pharma Equities - Novo Nordisk, Teva P... [Published Financial Services - Sep 26 2014]
Regulatory Approvals, Senior Notes Redemption, ... [Published Financial Services - Sep 25 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.